BioCentury | Mar 28, 2020

Sanofi adds to COVID-19 pipeline with Translate deal

A partnership with Translate Bio to develop an mRNA-based vaccine is one of multiple shots on goal Sanofi is preparing against COVID-19. The collaboration is part of a 2018 deal in which Sanofi (Euronext:SAN; NASDAQ:SNY)...
BioCentury | Mar 27, 2020

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

EMA’s CHMP backed conditional approval of an MAA for Zolgensma to treat spinal muscular atrophy in its March set of recommendations, which were made via a virtual meeting because of the COVID-19 outbreak. The agency...
BioCentury | Mar 27, 2020
Product Development

Pharmas to share assets in COVID-19 consortium led by Narasimhan, Gates

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation. Novartis AG (NYSE:NVS;...
BioCentury | Mar 26, 2020

FDA finally approves ozanimod for MS, satisfying first criterion for Bristol-Celgene CVR; launch delayed due to COVID-19

FDA’s approval of Celgene’s multiple sclerosis drug Zeposia ozanimod represents the first domino to fall among three that could lead to a big payout for Celgene’s former shareholders, who would be owed a contingent value...
BioCentury | Mar 26, 2020
Politics, Policy & Law

Revamped Senate stimulus bill would provide $27B to HHS to combat pandemic

The U.S. Senate’s latest COVID-19 stimulus bill would appropriate $340 billion to support local and national agencies to combat the pandemic, including billions for biopharma R&D. HHS’s Public Health and Social Services Emergency Fund would...
BioCentury | Mar 24, 2020
Product Development

Novavax’s flu data showcase vaccine platform’s potential

Pivotal data for Novavax’s flu vaccine provide validation of its recombinant nanoparticle vaccine platform as the biotech turns its technology towards developing a COVID-19 vaccine. Novavax Inc. (NASDAQ:NVAX) added $2.01 (19%) to $12.77 Tuesday. This...
BioCentury | Mar 22, 2020
Product Development

BARDA throws weight behind Kevzara, Actemra studies as IL-6 inhibition gains momentum for late-stage COVID-19

HHS will fund trials of Regeneron’s Kevzara and Genentech’s Actemra to treat COVID-19. Both IL-6 inhibitors, which will be evaluated in patients with later-stage disease and respiratory deterioration, entered pivotal studies in the past week....
BioCentury | Mar 21, 2020

Design debuts with $45M series A, portfolio against repeat expansions

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia. SR One led...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration

Eikonizo aims to shore up axonal transport to treat neurodegenerative diseases, starting with ALS; and to de-risk its programs, the company is developing a companion PET tracer to confirm target engagement in vivo.   The...
BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic. The Defense Research Advanced Projects...
Items per page:
1 - 10 of 6530